PI3K/p110β-specific inhibitors in castration-resistant prostate cancer / 中华男科学杂志
National Journal of Andrology
;
(12): 195-199, 2017.
Article
in Chinese
| WPRIM
| ID: wpr-812787
ABSTRACT
Advanced prostate cancer, especially at the castration-resistant stage, remains incurable clinically and, therefore, urgently requires new therapeutics for the patients. PI3K is a family of critical cell signal transduction molecules and their over-activation is an important factor in cancer development and progression. It has been demonstrated that class IA PI3K p110 is drastically overexpressed in prostate cancer and involved in androgen receptor-mediated gene expression and castration-resistant progression and regarded as a potential therapeutic target for prostate cancer. Several p110-specific inhibitors have been reported recently and two of them, GSK2636771 and AZD8186, are being tested in clinical trials.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Morpholines
/
Chromones
/
Phosphatidylinositol 3-Kinases
/
Therapeutic Uses
/
Protein Kinase Inhibitors
/
Drug Therapy
/
Prostatic Neoplasms, Castration-Resistant
/
Phosphoinositide-3 Kinase Inhibitors
/
Imidazoles
/
Aniline Compounds
Limits:
Humans
/
Male
Language:
Chinese
Journal:
National Journal of Andrology
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS